You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨再鼎醫藥-SB(9688.HK)放量反彈超6% 馬吉妥昔單抗的新藥申請獲受理
格隆匯 01-11 10:02
格隆匯1月11日丨日前創歷史新低的再鼎醫藥-SB(9688.HK)今日高開反彈,現漲超6%,報448.4港元,暫成交5788萬港元已超昨日全天成交額,總市值433億港元。近日,中國國家藥品監督管理局已受理公司馬吉妥昔單抗的新藥上市申請。馬吉妥昔單抗是一種靶向作用於HER2的Fc工程改造的新型單克隆抗體。根據再鼎醫藥新聞稿,該藥本次申請的適應症為聯合化療治療HER2陽性乳腺癌成人患者,這也是再鼎醫藥第6個被CDE受理的新藥上市申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account